Initial evidences about the usefulness of targeting epigenetic regulators for cancer treatment came from the DNA methyltransferase (DNMT) inhibitor 5-Azacytidine (5-Aza), which already in 1976 showed effectiveness in clinical trials for acute myeloid leukemia (AML) [3]. The gene discussed is DNMT1; the disease is acute myeloid leukemia.